Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Blue, do you have any idea how many sales reps large pharmas employ and how difficult it is to penetrate a market with a new drug across physician and hospital networks? And I am just talking about getting market share with a new drug by an established pharma salesforce network with physician and hospital relationships in place, not a small biotech trying to build a network of sales personal and physician and hospital relationships from scratch THEN try to generate market share of a new drug in a competitive immunotherapy market. IMO it's not realistic to think ADXS is going to try to develop into a standalone pharma in the US. Think how many delays and missteps we have seen under O'Connor getting through the clinical trials in an area that is becoming more crowded by the day. ADXS is already spread thin across all its trials, it would not be efficient from time and monetary aspect for ADXS to try to build out a distribution arm that attempts to compete with the resources of a large pharma. ADXS' strategy all along has been to retain manufacturing but outsource/license for commercialization/distribution.